Granted Patent
B2
US 12,378,194 · App. 17/824,861 · Granted Aug 5, 2025
N, n-dimethyltryptamine salts and crystalline salt forms
Assignee:
Atai Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A N,N-dimethyltryptamine (DMT) succinate crystalline form.
Claims (16)
1. A N,N-dimethyltryptamine (DMT) succinate crystalline Form A, characterized by an XRPD pattern having peaks at 16.90±0.2, 20.58±0.2, and 23.08±0.2°2θ.
2. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A is further characterized by at least one peak selected from 9.75±0.2, 14.27±0.2, 19.58±0.2, 23.39±0.2, 24.83±0.2, 26.79±0.2, and 27.6±0.2°2θ.
3. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A is further characterized by at least one peak selected from 9.75±0.2, 11.61±0.2, 13.28±0.2, 14.27±0.2, 14.72±0.2, 16.55±0.2, 17.36±0.2, 17.71±0.2, 18.82±0.2, 19.58±0.2, 20.30±0.2, 20.90±0.2, 21.51±0.2, 22.23±0.2, 22.50±0.2, 22.86±0.2, 23.39±0.2, 24.83±0.2, 25.17±0.2, 26.19±0.2, 26.79±0.2, 27.27±0.2, 27.60±0.2, 28.28±0.2, 28.79±0.2, 29.09±0.2, 29.58±0.2, 30.89±0.2, 31.16±0.2, 31.44±0.2, 31.97±0.2, 32.76±0.2, 32.95±0.2, 33.23±0.2, 33.76±0.2, and 34.45±0.2°2θ.
4. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A provides an XRPD pattern substantially in accordance with FIG. 2 .
5. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A exhibits a TGA thermograph substantially in accordance with FIG. 10 .
6. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A exhibits a DSC thermograph substantially in accordance with FIG. 10 .
7. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A exhibits a DVS isotherm substantially in accordance with FIG. 13 .
8. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A provides a variable temperature XRPD pattern substantially in accordance with FIG. 14 .
9. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A exhibits a DSC isotherm substantially in accordance with FIG. 15 .
10. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A provides an XRPD pattern substantially in accordance with FIG. 16 .
11. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A provides an XRPD pattern substantially in accordance with FIG. 17 .
12. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A provides a single crystal X-ray diffraction (SCXRD) pattern substantially in accordance with FIG. 17 .
13. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A exhibits a DVS isotherm substantially in accordance with FIG. 18 .
14. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A exhibits a TGA thermograph substantially in accordance with FIG. 19 .
15. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A exhibits a DSC thermograph substantially in accordance with FIG. 19 .
16. The DMT succinate crystalline Form A of claim 1 , wherein the crystalline Form A has a melting point of about 141.9° C. when measured under ambient conditions.
Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 29, 2024
From: PHARMACEUTICAL ADVISORS, LLC
To: ATAI LIFE SCIENCES AG
Reel/Frame 067552/0474 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 8, 2023
From: MORRA, NICHOLAS
To: PHARMACEUTICAL ADVISORS, LLC
Reel/Frame 065815/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 6, 2023
From: KASERA, SETU
To: ATAI THERAPEUTICS, INC.
Reel/Frame 065785/0909 →
CHANGE OF NAME
Recorded Nov 1, 2023
From: VIRIDIA LIFE SCIENCES, INC.
To: ATAI THERAPEUTICS, INC.
Reel/Frame 065416/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 25, 2023
From: ATAI LIFE SCIENCES AG
To: VIRIDIA LIFE SCIENCES, INC.
Reel/Frame 065345/0430 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 26, 2022
From: SHORT, GLENN; FAWAZ, MAJED
To: ATAI LIFE SCIENCES AG
Reel/Frame 060031/0224 →
Continuity (2)
Provisional Application
63192938
· May 25, 2021
References Cited (335)
US 3499003A
· Welstead, Jr.
· 1970
[cited by applicant]
US 5340838A
· Gidda et al.
· 1994
[cited by applicant]
US 5347029A
· Johnson
· 1994
[cited by applicant]
US 5637593A
· Porter et al.
· 1997
[cited by applicant]
US 5705527A
· Ishihara et al.
· 1998
[cited by applicant]
US 6201025B1
· Dax et al.
· 2001
[cited by applicant]
US 6436950B1
· Achari et al.
· 2002
[cited by applicant]
US 6500456B1
· Capella
· 2002
[cited by applicant]
US 8268856B2
· Hamann et al.
· 2012
[cited by applicant]
US 9388395B2
· Nazor et al.
· 2016
[cited by applicant]
US 20020052370A1
· Barber et al.
· 2002
[cited by applicant]
US 20030079301A1
· Sauter et al.
· 2003
[cited by applicant]
US 20050152858A1
· Bertz et al.
· 2005
[cited by applicant]
US 20050245594A1
· Sutter et al.
· 2005
[cited by applicant]
US 20070099909A1
· Chen et al.
· 2007
[cited by applicant]
US 20080248511A1
· Daily et al.
· 2008
[cited by applicant]
US 20080318957A1
· Glinka et al.
· 2008
[cited by applicant]
US 20090221549A1
· Gerber et al.
· 2009
[cited by applicant]
US 20120028995A1
· Ansorge et al.
· 2012
[cited by applicant]
US 20160106694A1
· Roberts et al.
· 2016
[cited by applicant]
US 20210015738A1
· LaRosa et al.
· 2021
[cited by applicant]
US 20210236523A1
· Schindler et al.
· 2021
[cited by applicant]
US 20210322306A1
· Espinoza et al.
· 2021
[cited by applicant]
US 20220024956A1
· Slassi et al.
· 2022
[cited by applicant]
US 20220031662A1
· Terwey
· 2022
[cited by applicant]
US 20220071958A1
· Terwey
· 2022
[cited by applicant]
US 20220079881A1
· Modi
· 2022
[cited by applicant]
US 20220273628A1
· Liechti et al.
· 2022
[cited by applicant]
US 20220304980A1
· Arnold et al.
· 2022
[cited by applicant]
US 20230041584A1
· Perni et al.
· 2023
[cited by applicant]
US 20230099972A1
· Rao et al.
· 2023
[cited by applicant]
US 20230136824A1
· Rao et al.
· 2023
[cited by applicant]
US 20230310374A1
· Rao et al.
· 2023
[cited by applicant]
US 20230322735A1
· Kruegel
· 2023
[cited by applicant]
US 20240116896A1
· Khan et al.
· 2024
[cited by applicant]
US 20240199544A1
· Fawaz et al.
· 2024
[cited by applicant]
US 20240287107A1
· Khan
· 2024
[cited by applicant]
EP 1336602A1
· 2003
[cited by applicant]
WO WO9506638A1
· 1995
[cited by applicant]
WO WO9617842A1
· 1996
[cited by applicant]
WO WO0041755A1
· 2000
[cited by applicant]
WO WO0051672A1
· 2000
[cited by applicant]
WO WO0211800A2
· 2002
[cited by applicant]
WO WO02068029A2
· 2002
[cited by applicant]
WO WO02068030A2
· 2002
[cited by applicant]
WO WO02068031A2
· 2002
[cited by applicant]
WO WO02068032A2
· 2002
[cited by applicant]
WO WO03000310A2
· 2003
[cited by applicant]
WO WO03020350A1
· 2003
[cited by applicant]
WO WO03026559A2
· 2003
[cited by applicant]
WO WO03082393A1
· 2003
[cited by applicant]
WO WO03084591A1
· 2003
[cited by applicant]
WO WO03090812A2
· 2003
[cited by applicant]
WO WO2006099416A1
· 2006
[cited by applicant]
WO WO2010151258A1
· 2010
[cited by applicant]
WO WO2011041870A1
· 2011
[cited by applicant]
WO WO2013063492A1
· 2013
[cited by applicant]
WO WO2018094106A2
· 2018
[cited by applicant]
WO WO2019081764A1
· 2019
[cited by applicant]
WO WO2019213551A1
· 2019
[cited by applicant]
WO WO2020037372A1
· 2020
[cited by applicant]
WO WO2020176597A1
· 2020
[cited by applicant]
WO WO2020181194A1
· 2020
[cited by applicant]
WO WO2020212951A1
· 2020
[cited by applicant]
WO WO2021226041A1
· 2021
[cited by applicant]
WO WO2021226416A1
· 2021
[cited by applicant]
WO WO2021244831A1
· 2021
[cited by applicant]
WO WO2021250434A1
· 2021
[cited by applicant]
WO WO2021250435A1
· 2021
[cited by applicant]
WO WO2022051670A1
· 2022
[cited by applicant]
WO WO2022061242A1
· 2022
[cited by applicant]
WO WO2022082058A1
· 2022
[cited by applicant]
WO WO2022109050A1
· 2022
[cited by applicant]
WO WO2022123232A1
· 2022
[cited by applicant]
WO WO2022150675A1
· 2022
[cited by applicant]
WO WO2022160056A1
· 2022
[cited by applicant]
WO WO2022170442A1
· 2022
[cited by applicant]
WO WO2022232179A1
· 2022
[cited by applicant]
WO WO2022235514A1
· 2022
[cited by applicant]
WO WO2022235529A1
· 2022
[cited by applicant]
WO WO2022246572A1
· 2022
[cited by applicant]
WO WO2022251351A1
· 2022
[cited by applicant]
WO WO2022261383A1
· 2022
[cited by applicant]
WO WO2023283386A2
· 2023
[cited by applicant]
WO WO2023021112A1
· 2023
[cited by applicant]
WO WO2023036473A1
· 2023
[cited by applicant]
WO WO2023055992A1
· 2023
[cited by applicant]
WO WO2023078604A1
· 2023
[cited by applicant]
WO WO2023111544A2
· 2023
[cited by applicant]
WO WO2023129956
· 2023
[cited by applicant]
WO WO2024054866A2
· 2024
[cited by applicant]
WO WO2024092106A2
· 2024
[cited by applicant]
WO WO2024130140A2
· 2024
[cited by applicant]
WO WO2024118767A2
· 2024
[cited by applicant]
WO WO2024119075A1
· 2024
[cited by applicant]
WO WO2024227149A2
· 2024
[cited by applicant]
Melting Point Determination, Melting Range (Year: 2012).
[cited by examiner]
The product Item No. 33586 of Cayman Chemical (Apr. 26, 2021) (Year: 2021).
[cited by examiner]
ACS Chem. Neurosci. 2018, 9, 1582-1590 (Year: 2018).
[cited by examiner]
Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use ACS Omega 2020, 5, 49, 32067-32075 (Year: 2020).
[cited by examiner]
Sigma Succinic acid—Butanedioic acid (Year: 2023).
[cited by examiner]
Berge et al., J. Pharm. Sci. 1977, vol. 66 1-18.
[cited by examiner]
“Safety Data Sheet”, Caymanchem.com, Cayman Chemical, Apr. 21, 2021, 6 pages., https://cdn.caymanchem.com/cdn/msds/33586m.pdf.
[cited by applicant]
Brito-Da-Costa, et al., Toxicokinetics and toxicodynamics of ayahuasca alkaloids N, N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: Clinical and forensic impact, Pharmaceuticals, Oct. 23, 2020, 36 …
[cited by applicant]
Dalgleish, et al., Transdiagnostic approaches to mental health problems: Current status and future directions, J. Consult Clin Psychology, Mar. 2020, pp. 179-195Mar, vol. 88, No. 3.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/030912, mailed Oct. 5, 2022, 20 pages.
[cited by applicant]
Sherwood, A.M., et al., “Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use”, Dec. 2, 2020, ACS Omega 2020, 5, 49, 32067-32075, https://doi.org/10.1021/acsomega.0c05099; entire document, especially a…
[cited by applicant]
Abiero et al., “Four Novel Synthetic Tryptamine Analogs Induce Head—Twitch Responses and Increase 5-HTR2a in the Prefrontal Cortex in Mice”, Biomol Ther (Seoul). Jan. 1, 2020; 28(1): 83-91.
[cited by applicant]
Andersson et al., “Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches”, Harm Reduction Journal, Dec. 2017, 10 pages.
[cited by applicant]
Archer et al., “5-Methoxy-N, N-dimethyltryptamine-induced analgesia is blocked by alpha-adrenoceptor antagonists in rats”, British J. Pharmac., Oct. 1986, pp. 293-298.
[cited by applicant]
Baker et al., “Neurochemical and neuropharmacological investigation of N-cyanoethyltryptamine, a potential prodrug of tryptamine”, Proc West Pharmacol Soc., 1987; 30: 307-11.
[cited by applicant]
Barker, “Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT”, Psychopharmacology (Berl). Jun. 2022; 239(6): 1749-1763. Epub Jan. 22, 2022, with erratu…
[cited by applicant]
Barsuglia et al., “Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study”, Front. Psychol., Dec. 2018, 6 pages.
[cited by applicant]
Benneyworth et al., “Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57BI/6J mice”, Psychopharmacology (2005) 179, 854-862.
[cited by applicant]
Berge, S.M. et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, Jan. 1977, vol. 66, No. 1, pp. 1-19.
[cited by applicant]
Buchwald, Peter, “Soft drugs: design principles, success stories, and future perspectives”, Expert Opin Drug Metab Toxicol. Aug. 2020; 16(8): 645-650. Epub Jun. 20, 2020.
[cited by applicant]
Bugaenko et al., “Synthesis of indoles: recent advances”, Russ. Chem. Rev., 2019, 88 (2)99-159, 62 pages.
[cited by applicant]
Cameron et al. “A non-hallucinogenic psychedelic analogue with therapeutic potential”, Nature; (2021), 589(7842): 474-479.
[cited by applicant]
Carhart-Harris et al., “Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms”, Scientific Reports, Oct. 2017, 7: 13187, 11 pages.
[cited by applicant]
Carhart-Harris et al., “The Therapeutic Potential of Psychedelic Drugs: Past, Present and Future”, Neuropsychopharmacology; 42, 2105-2113 (2017).
[cited by applicant]
Carter et al., “Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin”, Neuropsychopharmacology, Jun. 2005, pp. 1154-1162.
[cited by applicant]
CAS Registry No. 1152718-19-8, Benzenemethanamine, N-[4-(1,1-dimethylethyl)cyclohexyl]-2,4-difluoro-α-methyl-, Jun. 5, 2009, 1 page.
[cited by applicant]
CAS Registry No. 1152826-22-6, Benzenemethanamine, 5-bromo-N-[4-(1,1-dimethylpropyl)cyclohexyl]-2-fluoro-, Jun. 7, 2009, 1 page.
[cited by applicant]
CAS Registry No. 1154138-59-6, Benzenemethanamine, N-[4-(1,1-dimethylpropyl)cyclohexyl]-2,5-difluoro-, Jun. 9, 2009, 1 page.
[cited by applicant]
CAS Registry No. 127456-43-3, Phenol, 2-[[[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-4-(1,1-dimethylpropyl)-, trans- (9CI), Jun. 1, 1990, 1 page.
[cited by applicant]
CAS Registry No. 127456-44-4, 1H-Inden-5-ol, 6-[[[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-2,3-dihydro-, trans- (9CI), Jun. 1, 1990, 1 page.
[cited by applicant]
CAS Registry No. 127456-45-5, Phenol, 4-(1,1-dimethylethyl)-2-[[[4-(1,1-dimethylethyl) cyclohexyl]amino]methyl]-, trans- (9CI), Jun. 1, 1990, 1 page.
[cited by applicant]
CAS Registry No. 127456-46-6, Phenol, 4-(1,1-dimethylethyl)-2-[[[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-6-methyl-, hydrochloride, trans-(9CI), Jun. 1, 1990, 1 page.
[cited by applicant]
CAS Registry No. 127456-52-4, Phenol, 2-[[[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-4-(1-methylethyl)-, cis- (9CI), Jun. 1, 1990, 1 page.
[cited by applicant]
CAS Registry No. 127456-56-8, Phenol, 4-chloro-2-[[[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-, trans- (9CI), Jun. 1, 1990, 1 page.
[cited by applicant]
CAS Registry No. 127456-57-9, Phenol, 2-[[[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-4-fluoro-, trans- (9CI), Jun. 1, 1990, 1 page.
[cited by applicant]
CAS Registry No. 1308467-14-2, 1,2-Benzenediol, 3-[[[4-(1,1-dimethylpropyl)cyclohexyl]amino]methyl]-, Jun. 10, 2011, 1 page.
[cited by applicant]
CAS Registry No. 1405571-87-0, Benzenemethanamine, 2-bromo-N-[4-(1,1-dimethylpropyl)cyclohexyl]-5-fluoro-, Nov. 23, 2012, 1 page.
[cited by applicant]
CAS Registry No. 1406541-63-6, Phenol, 2-chloro-4-[[[4-(1,1-dimethylpropyl)cyclohexyl]amino]methyl]-, Nov. 25, 2012, 1 page.
[cited by applicant]
CAS Registry No. 1411655-23-6, Benzenemethanamine, N-[4-(1,1-dimethylpropyl)cyclohexyl]-2,3-difluoro-, Dec. 5, 2012, 1 page.
[cited by applicant]
CAS Registry No. 1456349-79-3, Benzenemethanamine, 2,3-dichloro-N-[4-(1,1-dimethylpropyl)cyclohexyl]-, Oct. 6, 2013, 1 page.
[cited by applicant]
CAS Registry No. 1458497-71-6, Benzenemethanamine, 2,4-dichloro-N-[4-(1,1-dimethylethyl)cyclohexyl]-α-methyl-, Oct. 15, 2013, 1 page.
[cited by applicant]
CAS Registry No. 1459328-13-2, Phenol, 2-bromo-4-[[[4-(1,1-dimethylpropyl)cyclohexyl]amino]methyl]-, Oct. 16, 2013, 1 page.
[cited by applicant]
CAS Registry No. 1490220-45-5, Benzenemethanamine, 2-bromo-5-chloro-N-[4-(1,1-dimethylpropyl)cyclohexyl]-, Dec. 8, 2013, 1 page.
[cited by applicant]
CAS Registry No. 1515984-46-9, Benzamide, N-(4-aminocyclohexyl)-3-chloro-N,5-dimethyl-, Jan. 10, 2014, 1 page.
[cited by applicant]
CAS Registry No. 1542027-51-9, Phenol, 3-chloro-2-[[[4-(1,1-dimethylpropyl)cyclohexyl]amino]methyl]-, Feb. 11, 2014, 1 page.
[cited by applicant]
CAS Registry No. 1624268-56-9, Benzamide, 4-[[[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-methyl-, Sep. 22, 2014, 1 page.
[cited by applicant]
CAS Registry No. 1712122-27-4, Benzenemethanamine, 5-chloro-N-[4-(1,1-dimethylpropyl)cyclohexyl]-2-fluoro-, May 25, 2015, 1 page.
[cited by applicant]
CAS Registry No. 1772618-27-5, Phenol, 3-[[[4-(1,1-dimethylpropyl)cyclohexyl]amino]methyl]-5-fluoro-, Jun. 3, 2015, 1 page.
[cited by applicant]
CAS Registry No. 1775706-37-0, Phenol, 2-chloro-6-[[[4-(1,1-dimethylpropyl)cyclohexyl]amino]methyl]-, Jun. 8, 2015, 1 page.
[cited by applicant]
CAS Registry No. 1858436-76-6, Bicyclo[3.1.0]hexan-2-amine, N-[(3-chloro-5-methylphenyl)methyl]-, Feb. 3, 2016, 1 page.
[cited by applicant]
CAS Registry No. 1931388-10-1, Benzenemethanamine, 2,5-dichloro-N-[4-(1,1- dimethylpropyl)cyclohexyl]-, Jun. 14, 2016, 1 page.
[cited by applicant]
CAS Registry No. 1939264-55-7, Phenol, 4-[[[4-(1,1-dimethylpropyl)cyclohexyl]amino]methyl]-2-fluoro-, Jun. 26, 2016, 1 page.
[cited by applicant]
CAS Registry No. 1939792-99-0, Benzenemethanamine, 5-bromo-2-chloro-N-[4-(1,1-dimethylpropyl)cyclohexyl]-, Jun. 27, 2016, 1 page.
[cited by applicant]
CAS Registry No. 1962333-15-8, Benzenemethanamine, N-[4-(1,1-dimethylpropyl)cyclohexyl]-5-fluoro-2-methyl-, Jul. 29, 2016, 1 page.
[cited by applicant]
CAS Registry No. 2032268-58-7, Cyclohexanecarboxylic acid, 4-[[(3-chloro-5-methylphenyl)methyl]amino]-, Nov. 15, 2016, 1 page.
[cited by applicant]
CAS Registry No. 2199998-08-6, Cyclohexanecarboxylic acid, 2-[[(3-chloro-5-methylphenyl)methyl]amino]-1-methyl-, Mar. 27, 2018, 1 page.
[cited by applicant]
CAS Registry No. 2202151-69-5, Cyclohexanecarboxylic acid, 3-[[(3-chloro-5-methylphenyl)methyl]amino]-, Mar. 30, 2018, 1 page.
[cited by applicant]
CAS Registry No. 2322790-81-6, Benzenemethanamine, N-[4-(1,1-dimethylethyl)cyclohexyl]-3-(trifluoromethyl)-, Jun. 2, 2019, 1 page.
[cited by applicant]
CAS Registry No. 2419600-39-6, Benzenemethanamine, 3-chloro-N-[4-(1,1-dimethylpropyl)cyclohexyl]-5-methyl-, Jun. 5, 2020, 1 page.
[cited by applicant]
CAS Registry No. 415970-94-4, Benzenemethanamine, N-[4-(1,1-dimethylethyl)cyclohexyl]-3,5-dimethoxy-, May 15, 2002, 1 page.
[cited by applicant]
CAS Registry No. 744981-83-7, Phenol, 2,6-dibromo-4-[[[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-, Sep. 15, 2004, 1 page.
[cited by applicant]
CAS Registry No. 793633-39-3, Phenol, 4-(1,1-dimethylethyl)-2-[[[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-6-methyl-, Dec. 6, 2004, 1 page.
[cited by applicant]
Chegaev, et al., “NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization”, Journal of pineal research, May 2007, pp. 371-385.
[cited by applicant]
Chen, et al., “Structure-activity relationships in a series of 5-[(2, 5-dihydroxybenzyl) amino] salicylate inhibitors of EGF-receptor-associated tyrosine kinase: importance of additional hydrophobic aromatic interaction…
[cited by applicant]
ClinicalTrials.gov, Effects of Dimethyltryptamine in Healthy Subjects (DMT), Apr. 20, 2020, 9 pages, entire document, especially p. 2 table, p. 4 table row 1. Retrieved on Jun. 24, 2022 from https://clinicaltrials.gov/c…
[cited by applicant]
Cocchi et al., “Novel Psychoactive Phenethylamines: Impact on Genetic Material”, International Journal of Molecular Sciences, 2020, 17 pages.
[cited by applicant]
Corne, “A Possible Correlation between Drug-Induced Hallucinations in Man and a Behavioural Response in Mice”, Psychopharmacologia. 1967; 11(1): 65-78.
[cited by applicant]
Custodio et al., “25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: evidence of abuse potential”, Addiction Biology, Nov. …
[cited by applicant]
Dakic et al., “Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT”, Scientific Reports, 2017, 13 pages.
[cited by applicant]
Davis et al., “5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety”, The American Journal of Drug and Alcohol Abuse, 20…
[cited by applicant]
Davis, et al., “The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption”, J Psychopharmacol, Jul. 2018; 32(7): 779…
[cited by applicant]
de Barros et al., “Synthesis of 25X-BOMes and 25X-NBOHs (X=H, I, Br) for pharmacological studies and as reference standards for forensic purposes”, Tetrahedron Letters, Mar. 2021, 4 pages.
[cited by applicant]
Dunlap et al., “Identification of psychoplastogenic N, N-dimethylaminoisotryptamine (isoDMT) analogues through structure-activity relationship studies”, J. Med. Chem. 2020, pp. 1142-1155.
[cited by applicant]
Durham, “Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug”, The Journal of Neuroscience, May 1, 1999, pp. 3423-3429.
[cited by applicant]
Glennon et al., “Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl-and indolylalkylamines”, Journal of Medicinal Chemistry, 1994, pp. 1929-1935.
[cited by applicant]
Glennon et al., “Synthesis and evaluation of a novel series of N,N-dimethylisotryptamines”, J Med Chem. Jan. 1984; 27(1): 41-5.
[cited by applicant]
Gonzalez-Maeso et al., “Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior”, Neuron, Feb. 2007, 53, 439-452.
[cited by applicant]
Gribble, “Recent developments in indole ring synthesis-methodology and applications”, Journal of the Chemical Society, Perkin Transactions, 2000, pp. 1045-1075.
[cited by applicant]
Grundke et al., “Photochemical α-Aminonitrile Synthesis Using Zn-Phthalocyanines as Near-Infrared Photocatalysts”, J Org Chem. May 6, 2022; 87(9): 5630-5642. Epub Apr. 14, 2022. With supporting information, 60 pages.
[cited by applicant]
Gurevich and Gurevich, “GPCR Signaling Regulation: The Role of GRKs and Arrestins”, Front Pharmacol. Feb. 19, 2019: 10: 125. eCollection 2019, 11 pages.
[cited by applicant]
Halberstadt et al., “Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice”, J Psychopharmacol., Nov. 2011, pp. 1548-1561.
[cited by applicant]
Halberstadt, “Recent Advances in the Neuropsychopharmacology of Serotonergic Hallucinogens”, Behav. Brain Res., 2015, pp. 99-120.
[cited by applicant]
Hamada et al., “Water-soluble prodrugs of dipeptide HIV protease inhibitors based on O→N intramolecular acyl migration: Design, synthesis and kinetic study”, Bioorg Med Chem., Jan. 2004, pp. 159-170.
[cited by applicant]
Hansen et al., “Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists”, Bioorganic & Medicinal Chemistry, 2015, pp. 3933-3937.
[cited by applicant]
Hansen et al., “Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists”, ACS Chemical Neuroscience, 2014, pp. 243-249.
[cited by applicant]
Harriott et al., “Animal models of migraine and experimental techniques used to examine trigeminal sensory processing”, J Headache Pain. Aug. 29, 2019; 20(1): 91. 15 pages.
[cited by applicant]
Healthline, “How Long Does DMT Last?”, Nov. 2019, 12 pages, entire document, especially p. 1 para 1-3. Retrieved om Jun. 24, 2022 from https://www.healthline.com/health/how-long-does-dmt-last.
[cited by applicant]
Humphrey, et al., “Practical methodologies for the synthesis of indoles”, Chem. Review, Jul. 2006, pp. 2875-2911.
[cited by applicant]
Huttunen, et al., “Prodrugs-from Serendipity to Rational Design”, Pharmacal Rev., Sep. 2011, pp. 750-771.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/026396 dated Nov. 9, 2023, 8 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/026396, mailed Jul. 28, 2022, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/032918, mailed Oct. 12, 2022, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/045336 dated Jan. 13, 2023, 14 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2022/030912, mailed Jul. 28, 2022, 8 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2022/032918, mailed Aug. 12, 2022, 2 pages.
[cited by applicant]
Invitation to pay additional fees for International Application No. PCT/US2023/073574, dated Nov. 6, 2023, 2 pages.
[cited by applicant]
Invitation to Pay Fee for International Application No. PCT/US2022/082465 dated Mar. 16, 2023, 3 pages.
[cited by applicant]
Kaminska et al., “25C-NBOMe short characterization”, Forensic Toxicology, 2020, pp. 490-495.
[cited by applicant]
Klein, et al, “Structure-activity relationships in potentially hallucinogenic N, N-dialkyltryptamines substituted in the benzene moiety”, J. Med. Chen, Aug. 1982, pp. 908-913.
[cited by applicant]
Klein et al., “Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships”, J Pharmacol Exp Ther. Jun. 2011; …
[cited by applicant]
Kraehenmann et al., “Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation”, Psychopharmacology, 2017, pp. 2031-2046.
[cited by applicant]
Kraehenmann et al., “LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation”, Front. Pharmacol., 2017, 9 pages.
[cited by applicant]
Krise, J. P., et al., “Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs”, J Med Chem. Aug. 12, 1999; 42(16): 3094-100.
[cited by applicant]
Kucklander, et al., “Darstellung und Oxidation von 2-(2, 5-Dihydroxy-phenyl)-ethylamin-Derivaten, II/Synthesis and Oxidation of 2-(2, 5-Dihydroxyphenyl)-ethylamine Derivatives, II”, Zeitschrift für Naturforschung B, 198…
[cited by applicant]
Li et al., “Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced elF4E proteasomal…
[cited by applicant]
Lima da Cruz et al., “Corrigendum: A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus”, Front. Mol. Neurosci., 2018…
[cited by applicant]
Lyon et al., “Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens”, European Journal of Pharmacology, 1988, pp. 291-297.
[cited by applicant]
Madsen et al., “Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity”, medRxiv. Jul. 10, 2022: Jul. 2022.
[cited by applicant]
Madsen et al., “Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels”, Neuropsychopharmacology (2019) 44: 1328- 1334.
[cited by applicant]
McBride, “Bufotenine: Toward an Understanding of Possible Psychoactive Mechanisms”, Journal of Psychoactive Drugs, Jul.-Sep. 2000, pp. 321-331.
[cited by applicant]
McClure-Begley and Roth, “The promises and perils of psychedelic pharmacology for psychiatry”, Nat Rev Drug Discov. Jun. 2022; 21(6): 463-473. Epub Mar. 17, 2022.
[cited by applicant]
Mertens and Preller, “Classical Psychedelics as Therapeutics in Psychiatry—Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders”, Pharmacopsychiatry. Jul. 2021; 54(4): 176-1…
[cited by applicant]
Milne et al., “Metabolic engineering of
[cited by applicant]
Mithoefer et al., “The safety and efficacy of±3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot …
[cited by applicant]
National Center for Biotechnology Information (2023). PubChem Substance Record for SID 309311543, SID 309311543, Source: Aurora Fine Chemicals LLC. Modified Jan. 30, 2016, retrieved Nov. 7, 2023, from https://pubchem.nc…
[cited by applicant]
Nichols, “Hallucinogens”, Pharmacol. Ther., 2004, pp. 131-181.
[cited by applicant]
Nichols, “Structure-Activity Relationships of Phenethylamine Hallucinogens”, J. Pharm. Sciences, 1981, pp. 839-849.
[cited by applicant]
Olson, David E., “The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects”, ACS Pharmacol Transl Sci. Apr. 9, 2021; 4(2): 563-567. Published online Dec. 10, 2020.
[cited by applicant]
Ott, J., “Pharmepena-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-N, N-dimethyl-tryptamine”, Journal of Psychoactive Drugs, Dec. 2001, pp. 403-407.
[cited by applicant]
Ott, J., “Pharmañopo-Psychonautics: Human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine”, Journal of Psychoactive Drugs, Sep. 2001, pp. 273-281.
[cited by applicant]
Pandy-Szekeres et al., “GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources”, Nucleic Acids Res. Jan. 6, 2023; 51(D1): D395-D402.
[cited by applicant]
Pokorny et al., “Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience”, Eur. Neuropsychopharmacol., Apr. 2016, pp. …
[cited by applicant]
Pottie, et al., “Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays”, Biochemical pharmacology, Dec. 2020…
[cited by applicant]
Preller et al., “Effects of serotonin 2A/1A receptor stimulation on social exclusion processing”, PNAS, May 3, 2016, vol. 113, No. 18, 5119-5124.
[cited by applicant]
Preller et al., “Role of the 5-HT2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study”, J. Neurosci., Apr. 2018, 38(14): 3603-3611.
[cited by applicant]
Preller et al., “The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation”, Current Biology, Feb. 2017, pp. 451-457.
[cited by applicant]
PubChem SID 385740476, 2-(2,5-dimethoxy-4-(propan-2-yt)phenyl)-N-(2methoxybenzyl)ethanamine, Sep. 23, 2019, 6 pages, retrieved from https://pubchem.ncbi.nlm.nih.gov/substance/385740476.
[cited by applicant]
Pubchem, SID 627609, Sep. 2004, 8 pages. Retrieved from the Internet: https://pubchem.ncbi.nlm.nih.gov/substance/627609.
[cited by applicant]
PubChem-SID-310331158, Modify Date: Feb. 15, 2015, p. 2.
[cited by applicant]
PubChem-SID-369863280, Modify Date: May 25, 2018, p. 2.
[cited by applicant]
Puledda et al., “An update on migraine: current understanding and future directions”, J Neurol (2017) 264:2031-2039.
[cited by applicant]
Ray, T., “Psychedelics and the Human Receptorome”, PLoS One (2010) 5(2): e9019, 17 pages.
[cited by applicant]
Riba, et al., “Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study”, Drug Test Anal. May 2015;7(5): 401-6. Epub Jul. 28, 2014.
[cited by applicant]
Roth et al., “High-affinity Agonist Binding Is Not Sufficient for Agonist Efficacy at 5-Hydroxytryptamine2A Receptors: Evidence in Favor of a Modified Ternary Complex Model”, The Journal of Pharmacology and Experimental…
[cited by applicant]
Ruiz et al., “Routes of Drug Administration: Dosage, Design, and Pharmacotherapy Success”, Routes of Drug Administration, Chapter 6, Jan. 2018, 43 pages.
[cited by applicant]
Sargent et al., “Radiohalogen-Labeled Imaging Agents. 3. Compounds for Measurement of Brain Blood Flow by Emission Tomography”, Journal of Medicinal Chemistry (1984), 27(8), 1071-1077.
[cited by applicant]
Schifano et al., “New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review”, Experimental Neurology (2021), 339, 113638 (Author manuscript, 29 pages).
[cited by applicant]
Schindler et al., “Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin”, Neurotherapeutics, Jan. 2021; 18(1): 534-543. doi: 10.1007/s13311-020-00962-y. Epub Nov. 12, 2020.
[cited by applicant]
Shen et al., “Psychedelic 5-Methoxy-N,N-dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions”, Curr Drug Metab., Oct. 2010 ; 11(8): 659-666.
[cited by applicant]
Sizemore, T.R, and Dacks, A.M., “Circadian Clocks: Mosquitoes Master the Dark Side of the Room”, Curr Biol. Aug. 17, 2020; 30(16): R932-R934.
[cited by applicant]
Strassman, “Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects”, Arch Gen Psychiatry. Feb. 1994; 51(2): 85-97.
[cited by applicant]
Strassman, “N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale”, Arch Gen Psychiatry. Feb. 1994; 51(2): 98-108.
[cited by applicant]
Substance Record for SID 433987242 to PubChem (hereinafter, “PubChem '242”), Sep. 2020, 7 pages.
[cited by applicant]
Terry, Alvin V., “Drugs that target serotonergic receptors”, Cognitive Enhancing Drugs, Introduction, pp. 79-80, 2004, 2 pages.
[cited by applicant]
Third Party Observation received for International Application No. PCT/US2022/045336, filed May 24, 2023 and received Jun. 2, 2023, 8 pages.
[cited by applicant]
Tirapegui et al., “Synthesis of N-(halogenated) benzyl analogs of superpotent serotonin ligands”, J. Chil. Chem. Soc., (2014) 59, No. 3, pp. 2625-2627.
[cited by applicant]
Titeler et al., “Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens”, Psychopharmacology (1988) 94, 213-216.
[cited by applicant]
Tomaszewski et al., “Benzofuran Bioisosteres of Hallucinogenic Tryptamines”, J. Med. Chem., 1992, 35, pp. 2061-2064.
[cited by applicant]
United States Patent and Trademark Office, International Search Report and Written Opinion for International Application No. PCT/US2022/082465 dated Jun. 6, 2023, 11 pages.
[cited by applicant]
Uthaug et al., “A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, min…
[cited by applicant]
Uthaug et al., “Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment”, Psychopharmacology (2020) 237: 773-785.
[cited by applicant]
Valle et al., “Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans”, Eur. Neuropsychopharm (2016) 26, 1161-1175 (Author-edited version, 23 pages).
[cited by applicant]
Vollenweider et al., “Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action”, Neuroreport (1998) 9, 3897-3902 (8 pages).
[cited by applicant]
Vollenweider et al., “Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders”, Nature Reviews Neuroscience, Nov. 2020, vol. 21, pp. 611-624.
[cited by applicant]
Wang et al., “Anti-inflammatory and analgesic actions of bufotenine through inhibiting lipid metabolism pathway”, Biomedicine & Pharmacotherapy (2021) 140: 111749, 11 pages.
[cited by applicant]
Wey, “Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors”, Journal of medicinal chemistry, Dec. 2007, pp. 6367-6382.
[cited by applicant]
Wikipedia, “Perfusion”, Dec. 29, 2020 (Dec. 29, 2020), retrieved on Jun. 24, 2022 from https://en.wikipedia.org/w/index.php?title=Perfusion&oldid=996968059; entire document, especially p. 1 para 1.
[cited by applicant]
Winter et al., “Psilocybin-induced stimulus control in the rat”, Pharmacol. Biochem. Behav. (2007) 87, 472-480 (18 pages).
[cited by applicant]
Winter et al., “The Paradox of 5-Methoxy-N,N-Dimethyltryptamine: An Indoleamine Hallucinogen That Induces Stimulus Control Via 5-HT1A Receptors,” Pharmacology Biochemistry and Behavior, 2000, vol. 65, No. 1, pp. 75-82.
[cited by applicant]
Wood et al., “Prevalence of use and acute toxicity associated with the use of NBOMe drugs”, Clinical Toxicology, 2015, 53: 85-92.
[cited by applicant]
Yu, A.M., “Indolealkylamines: Biotransformations and Potential Drug-Drug Interactions”, The AAPS Journal, Jun. 2008, vol. 10, No. 2, pp. 242-253.
[cited by applicant]
Zamberlan et al., “The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptam…
[cited by applicant]
Barker, “N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function,” Front Neurosci. Aug. 6, 2018:12: 536. doi: 10.3389/fnins.2018.00536. eCollectio…
[cited by applicant]
Bergin, “The structure of the catecholamines. II. The crystal structure of dopamine hydrochloride.” Acta Crystallogr B Struct Crystallogr Cryst Chem. Nov. 15, 1968; 24(11): 1506-10. doi: 10.1107/s0567740868004553.
[cited by applicant]
Bibi et al., “Use of Permeapad® for prediction of buccal absorption: A comparison to in vitro, ex vivo and in vivo method,” Eur J Pharm Sci. Oct. 10, 2016: 93: 399-404. doi:10.1016/j.ejps.2016.08.041. Epub Aug. 24, 2016.
[cited by applicant]
Brandt et al., “Analytical methods for psychoactive N,N-dialkylated tryptamines,” Trends in Analytical Chemistry, vol. 29, No. 8, 2010, pp. 858-869.
[cited by applicant]
Carvalho et al., “Mucoadhesive drug delivery systems,” BJPS, vol. 46, n. 1, Jan./Mar. 2010. 18 pages.
[cited by applicant]
Falkenberg et al., “The crystal and molecular structure of (N,N)-dimethyltryptamine.” Acta Crystallogr., Sect B28, 3075-3083, https://doi.org/10.1107/S0567740872007435. 9 pages.
[cited by applicant]
Gaujac et al. “Determination of N,N-dimethyltryptamine in beverages consumed in religious practices by headspace solid-phase microextraction followed by gas chromatography ion trap mass spectrometry,” Talanta. Mar. 15, …
[cited by applicant]
Glatfelter G, et al., “Synthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines,” ACS Omega, Jul. 2022, vol. 7(28), pp. 24888-24894.
[cited by applicant]
Griffiths, R. R., et al. “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial,” Journal of Psychopharmacology 30(12…
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/030912 dated Dec. 7, 2023, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/032918 dated Dec. 21, 2023, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/045336, mailed Apr. 11, 2024, 7 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/073574 dated Feb. 16, 2024, 13 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/077879, mailed Apr. 4, 2024, 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/082080, mailed Apr. 4, 2024, 8 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2023/084319 mailed May 20, 2024, 13 pages.
[cited by applicant]
Malaca S et al., “Toxicology and Analysis of Psychoactive Tryptamines”, International Journal of Molecular Science, Dec. 2020, vol. 21(23), pp. 1-30.
[cited by applicant]
Puri et al., “Thiolation of Biopolymers for Developing Drug Delivery Systems with Enhanced Mechanical and Mucoadhesive Properties: A Review,” Polymers (Basel). Aug. 11, 2020; 12(8): 1803. doi: 10.3390/polym12081803. 27 …
[cited by applicant]
Shen L, et al., “Bufotenines-loaded liposome exerts anti-inflammatory, analgesic effects and reduce gastrointestinal toxicity through altering lipid and bufotenines metabolism”, Biomed Pharmacother, Sep. 2022, vol. 153,…
[cited by applicant]
Banker, G. S., et al., “Prodrugs”, Modern Pharmaceutics, Third Edition, Revised, and Expanded, Marcel Dekker, Inc. (1996); pp. 451 and 596.
[cited by applicant]
Bergin, “Preliminary X-ray crystallographic study of some psychoactive indole bases,” Department of Medical Physics, Feb. 13, 1968, 1 page.
[cited by applicant]
Declaration of Majed Fawaz under 37 C.F.R. § 1.130, dated Jun. 2024, 2 pages.
[cited by applicant]
Gaujac et al., “Investigations into the polymorphic properties of N, N-dimethyltryptamine by X-ray diffraction and differential scanning calorimetry,” Microchemical Journal 110, Mar. 2, 2013, 12 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/026797 mailed Sep. 6, 2024, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/049678, mailed Jan. 21, 2025, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/036639 mailed Sep. 23, 2024, 11 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/038804 mailed Dec. 17, 2024, 14 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/039503 mailed Nov. 5, 2024, 17 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/045494 mailed Nov. 15, 2024, 11 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2024/026797 mailed Jun. 25, 2024, 2 pages.
[cited by applicant]
Invitation to Pay Additional fees for International Application No. PCT/US2024/038804, mailed Sep. 23, 2024, 3 pages.
[cited by applicant]
Invitation to pay additional fees for International Application No. PCT/US2024/039503, dated Sep. 10, 2024, 2 pages.
[cited by applicant]
Pubchem CID 156821129, created Nov. 20, 2021, Modify date Aug. 23, 2024, available at: https://pubchem.ncbi.nlm.nih.gov/compound/156821129, 10 pages.
[cited by applicant]
Pubchem CID 6089, Dimethyltryptamine, Create date: Mar. 26, 2005 (Mar. 26, 2005), 6 pages.
[cited by applicant]
Pubchem CID 88309097, Created date Feb. 12, 2015, Modified date Nov. 9, 2024, available at: https://pubchem.ncbi.nlm.nih.gov/compound/88309097, 8 pages.
[cited by applicant]
Thoai, et al., “Design and Synthesis of Sustain-Acting Melatonin Prodrugs”, Sep. 12, 2013 (Sep. 12, 2013), Journal of Chemistry, vol. 2013, Issue 1, pp. 1-6.
[cited by applicant]
Wolff, M., “Burger's Medicinal Chemistry and Drug Discovery”, Fifth Edition, John Wiley & Sons (1995); 1: 975-977.
[cited by applicant]
Cited By (5)